Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy

<p>Supplementary Figure S4.</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Laura Boucai (15054310) (author)
Diğer Yazarlar:	Mahesh Saqcena (15054313) (author), Fengshen Kuo (14947443) (author), Ravinder K. Grewal (15054316) (author), Nicholas Socci (15054319) (author), Jeffrey A. Knauf (15008595) (author), Gnana P. Krishnamoorthy (15054322) (author), Mabel Ryder (15054325) (author), Alan L. Ho (15054328) (author), Ronald A. Ghossein (15054331) (author), Luc G.T. Morris (14956461) (author), Venkatraman Seshan (15054334) (author), James A. Fagin (15054337) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Biomarkers Prognostic biomarkers Endocrine-Related Cancers Precision Medicine
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
Yazar:: Laura Boucai (15054310)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Additional Oncogenic Alterations in <i>RAS</i>-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes
Yazar:: Athanasios Bikas (16006076)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
Yazar:: Naveen S. Vasudev (15057037)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
Yazar:: Naveen S. Vasudev (15057037)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Yazar:: Hansol Lee (15054787)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Yazar:: Yansong Lin (16374208)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 2 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
Yazar:: Anna Eriksson (15352461)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table1 from Somatic Exonic Deletions in <i>RUNX1</i> Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid Leukemia
Yazar:: Anna Eriksson (15352461)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Yazar:: Raphaël Leman (17314506)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Yazar:: Raphaël Leman (17314506)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Yazar:: Raphaël Leman (17314506)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Yazar:: Raphaël Leman (17314506)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S5 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Yazar:: Raphaël Leman (17314506)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
Yazar:: Raphaël Leman (17314506)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
Yazar:: Katleen Janssens (15053356)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Yazar:: Jamunarani Veeraraghavan (16461809)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
Yazar:: Iris van 't Erve (15054503)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Yazar:: Nicola S. Meagher (15048462)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Yazar:: Nicola S. Meagher (15048462)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Yazar:: Nicola S. Meagher (15048462)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables S1-S11 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Yazar:: Nicola S. Meagher (15048462)
Baskı/Yayın Bilgisi: (2025)

Table 1 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Yazar:: Nicola S. Meagher (15048462)
Baskı/Yayın Bilgisi: (2025)

Table 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Yazar:: Nicola S. Meagher (15048462)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_mf0d4albc9i7num68hau97hrn5